-
1.发明授权QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS 有权Quinazolones衍生物作为ALFA 1A / B肾上腺素受体拮抗剂
公开(公告)号：EP1363899B1
公开(公告)日：2005-05-11
申请号：EP01985417.3
申请日：2001-12-17
发明人： BECKER, Cyrus, Kephra , CAROON, Jon, Marie , MELVILLE, Chris, Richard , PADILLA, Fernando , PFISTER, Juerg, Roland , ZHANG, Xiaoming
IPC分类号： C07D401/04 , C07D417/04 , C07D471/04 , A61K31/549 , A61P13/08
CPC分类号： C07D417/04 , C07D401/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D417/14 , C07D471/04 , C07D471/14 , C07D487/04 , C07D491/04
摘要： This invention relates to compounds which are generally alpha-1A/B adrenoceptor antagonists and which are represented by formula (I) wherein Z is -C(O)- or -S(O)2-, X is carbon or nitrogen, Y is carbon, and X-Y considered together are two adjoining atoms of the ring A, said ring being a fused aromatise ring of five to six atoms per ring optionally incorporating one to two heteroatoms per ring; chosen from N, O, or S; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their preparation and their use as therapeutic agents.
-
2.发明公开QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS 有权Quinazolones衍生物作为ALFA 1A / B肾上腺素受体拮抗剂
公开(公告)号：EP1363899A1
公开(公告)日：2003-11-26
申请号：EP01985417.3
申请日：2001-12-17
发明人： BECKER, Cyrus, Kephra , CAROON, Jon, Marie , MELVILLE, Chris, Richard , PADILLA, Fernando , PFISTER, Juerg, Roland , ZHANG, Xiaoming
IPC分类号： C07D401/04 , C07D417/04 , C07D471/04 , A61K31/549 , A61P13/08
CPC分类号： C07D417/04 , C07D401/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D417/14 , C07D471/04 , C07D471/14 , C07D487/04 , C07D491/04
摘要： This invention relates to compounds which are generally alpha-1A/B adrenoceptor antagonists and which are represented by formula (I) wherein Z is -C(O)- or -S(O)2-, X is carbon or nitrogen, Y is carbon, and X-Y considered together are two adjoining atoms of the ring A, said ring being a fused aromatise ring of five to six atoms per ring optionally incorporating one to two heteroatoms per ring; chosen from N, O, or S; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their preparation and their use as therapeutic agents.
-
搜索结果
2 条记录 (耗时 0.018 秒)
